Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study"

J Clin Lipidol. 2019 Mar-Apr;13(2):287-300. doi: 10.1016/j.jacl.2019.01.009. Epub 2019 Jan 25.

Abstract

Background: There is a lack of information on the health care of familial hypercholesterolemia (FH).

Objective: The objective of this study was to compare the health care of FH in countries of the Asia-Pacific region and Southern Hemisphere.

Methods: A series of questionnaires were completed by key opinion leaders from selected specialist centers in 12 countries concerning aspects of the care of FH, including screening, diagnosis, risk assessment, treatment, teaching/training, and research; the United Kingdom (UK) was used as the international benchmark.

Results: The estimated percentage of patients diagnosed with the condition was low (overall <3%) in all countries, compared with ∼15% in the UK. Underdetection of FH was associated with government expenditure on health care (ϰ = 0.667, P < .05). Opportunistic and systematic screening methods, and the Dutch Lipid Clinic Network criteria were most commonly used to detect FH; genetic testing was infrequently used. Noninvasive imaging of coronary calcium and/or carotid plaques was underutilized in risk assessment. Patients with FH were generally not adequately treated, with <30% of patients achieving guideline recommended low-density lipoprotein cholesterol targets on conventional therapies. Treatment gaps included suboptimal availability and use of lipoprotein apheresis and proprotein convertase subtilsin-kexin type 9 inhibitors. A deficit of FH registries, training programs, and publications were identified in less economically developed countries. The demonstration of cost-effectiveness for cascade screening, genetic testing, and specialized treatments were significantly associated with the availability of subsidies from the health care system (ϰ = 0.571-0.800, P < .05).

Conclusion: We identified important gaps across the continuum of care for FH, particularly in less economically developed countries. Wider implementation of primary and pediatric care, telehealth services, patient support groups, education/training programs, research activities, and health technology assessments are needed to improve the care of patients with FH in these countries.

Keywords: Asia-pacific region; Facilities; Familial hypercholesterolemia; Health care; Services; Southern hemisphere.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Component Removal
  • Cardiovascular Diseases / complications
  • Cholesterol, LDL / blood
  • Delivery of Health Care / economics
  • Delivery of Health Care / statistics & numerical data*
  • Diet Therapy
  • Health Care Costs / statistics & numerical data
  • Health Education
  • Humans
  • Hyperlipoproteinemia Type II / complications
  • Hyperlipoproteinemia Type II / economics
  • Hyperlipoproteinemia Type II / epidemiology*
  • Hyperlipoproteinemia Type II / therapy
  • Insurance, Health, Reimbursement
  • Internationality
  • PCSK9 Inhibitors
  • Registries
  • Risk Assessment
  • Serine Proteinase Inhibitors / pharmacology
  • Serine Proteinase Inhibitors / therapeutic use

Substances

  • Cholesterol, LDL
  • PCSK9 Inhibitors
  • Serine Proteinase Inhibitors
  • PCSK9 protein, human